Clinical Update provided on Ph 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety and Efficacy Data Observed in a Patient with MDS/AML January 11, 2026
FDA grants Orphan Drug Designation for AJ1-11095 for the Treatment of Myelofibrosis December 15, 2025
Bexmarilimab to advance into registrational Ph 2/3 study in 1L HR-MDS after positive meeting with the FDA August 19, 2025
Patient deaths trigger discontinuation of Ph 1 trial from SGR-2921 Program in R/R AML and HR-MDS patients August 19, 2025
Global Registrational Ph 3 Study of Lisaftoclax for 1L Higher-Risk MDS Cleared by US FDA and EMA August 19, 2025
FAILED TRIAL: Ph 3 VERONA of venetoclax + azacitidine in 1L higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of OS June 17, 2025
Reprioritized pipeline focus on LAVA-1266 and plan to discontinue development of LAVA-1207 December 18, 2024
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials December 10, 2024
FAILED TRIAL: Topline Data Announced from SELECT-MDS-1 Ph 3 Trial of Tamibarotene in Higher-Risk MDS with RARA Gene Overexpression November 19, 2024
